Deutsche Bank AG Takes Position in Pediatrix Medical Group, Inc. $MD

Key Points

• Deutsche Bank acquired 86,424 shares of Pediatrix Medical Group during the second quarter, worth approximately $2.19 million and representing a 0.11% stake. Institutional investors collectively own 97.71% of the company.
• Pediatrix exceeded quarterly expectations, reporting $0.63 in EPS versus the $0.59 consensus estimate and $487.78 million in revenue, up 4.1% year over year.
• Analyst sentiment remains cautious: seven analysts rate the stock “Hold,” with a consensus price target of $25.00, below its reported opening price of $26.81.

Deutsche Bank AG acquired a new position in Pediatrix Medical Group, Inc. (NYSE:MD - Free Report) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 86,424 shares of the company's stock, valued at approximately $2,189,000. Deutsche Bank AG owned 0.11% of Pediatrix Medical Group as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also made changes to their positions in MD. Keybank National Association OH grew its holdings in Pediatrix Medical Group by 2.0% in the 1st quarter. Keybank National Association OH now owns 22,941 shares of the company's stock valued at $491,000 after buying an additional 458 shares during the last quarter. Gotham Asset Management LLC lifted its holdings in shares of Pediatrix Medical Group by 0.6% during the third quarter. Gotham Asset Management LLC now owns 116,093 shares of the company's stock worth $1,945,000 after buying an additional 724 shares during the last quarter. ProShare Advisors LLC lifted its holdings in shares of Pediatrix Medical Group by 4.6% during the fourth quarter. ProShare Advisors LLC now owns 16,816 shares of the company's stock worth $360,000 after buying an additional 734 shares during the last quarter. Verition Fund Management LLC boosted its position in shares of Pediatrix Medical Group by 4.4% in the third quarter. Verition Fund Management LLC now owns 25,408 shares of the company's stock valued at $426,000 after acquiring an additional 1,066 shares during the period. Finally, EverSource Wealth Advisors LLC boosted its position in shares of Pediatrix Medical Group by 77.7% in the first quarter. EverSource Wealth Advisors LLC now owns 2,515 shares of the company's stock valued at $54,000 after acquiring an additional 1,100 shares during the period. Institutional investors and hedge funds own 97.71% of the company's stock.

Pediatrix Medical Group Price Performance

Shares of Pediatrix Medical Group stock opened at $26.81 on Friday. The firm has a market cap of $2.18 billion, a P/E ratio of 12.83 and a beta of 0.66. The firm's 50-day simple moving average is $26.00 and its 200-day simple moving average is $23.15. Pediatrix Medical Group, Inc. has a twelve month low of $15.69 and a twelve month high of $27.94. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.32 and a current ratio of 1.32.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.59 by $0.04. The firm had revenue of $487.78 million during the quarter, compared to analyst estimates of $478.49 million. Pediatrix Medical Group had a net margin of 8.96% and a return on equity of 20.05%. The company's quarterly revenue was up 4.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.53 earnings per share. As a group, research analysts expect that Pediatrix Medical Group, Inc. will post 2.17 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Jefferies Financial Group downgraded shares of Pediatrix Medical Group from a "buy" rating to a "hold" rating and raised their price objective for the stock from $27.00 to $28.00 in a research note on Wednesday, August 19th. Weiss Ratings cut shares of Pediatrix Medical Group from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Tuesday. UBS Group increased their price target on shares of Pediatrix Medical Group from $25.00 to $28.00 and gave the company a "neutral" rating in a report on Thursday, August 6th. Truist Financial raised their price target on shares of Pediatrix Medical Group from $23.00 to $28.00 and gave the stock a "hold" rating in a research report on Tuesday, July 14th. Finally, Deutsche Bank Aktiengesellschaft restated a "hold" rating and set a $25.00 price objective on shares of Pediatrix Medical Group in a report on Wednesday, August 5th. Seven investment analysts have rated the stock with a Hold rating, According to data from MarketBeat, Pediatrix Medical Group currently has an average rating of "Hold" and a consensus price target of $25.00.

Pediatrix Medical Group Profile

Pediatrix Medical Group, Inc NYSE: MD is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.

Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pediatrix Medical Group, Inc. (NYSE:MD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source